ijms-logo

Journal Browser

Journal Browser

The Molecular Pharmaceutics and Drug Delivery

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".

Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 6376

Special Issue Editor


E-Mail Website
Guest Editor
Intelligent Nanohybrid Materials Laboratory (INML), Institute of Tissue Regeneration Engineering (ITREN), Dankook University, Cheonan Campus, Cheonan 31116, Republic of Korea
Interests: drug delivery; cancer therapy; anti-viral formulations; curcumin formulations; inorganic nano-hybrids
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Advanced pharmaceutical approaches have been merged into various biomedical applications, such as drug delivery, with tremendous potential in treating different kinds of pathological conditions such as cancer and viral diseases, among others. In particular, rationally designed molecular self-assembled nanomaterials—organic, inorganic, and their composites—have shown a wide variety of applications toward early diagnosis and therapy. For this Special Issue, we invite you to show case such molecularly engineered micro-/nanomaterials having selective applications towards drug delivery and related research areas. I welcome you to take this advantage of this unique opportunity to present your excellent scientific results and advancements to other researchers and readers interested in the latest developments in molecular pharmaceutics and drug delivery.

Dr. N. Sanoj Rejinold
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • molecular engineering
  • molecular Pharmaceutics
  • pharmacology
  • pharmaceutical formulations
  • oral drug delivery systems
  • organic formultions
  • hybrid/composite nanomaterials
  • self assebled nanostructures
  • vaccine therapy
  • oral anti-cancer formulations
  • theranosis

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

30 pages, 1855 KiB  
Review
Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD)
by Aira Sarkar, Vijayabhaskarreddy Junnuthula and Sathish Dyawanapelly
Int. J. Mol. Sci. 2021, 22(19), 10594; https://doi.org/10.3390/ijms221910594 - 30 Sep 2021
Cited by 20 | Viewed by 5550
Abstract
Age-related macular degeneration (AMD) is the leading cause of vision loss in geriatric population. Intravitreal (IVT) injections are popular clinical option. Biologics and small molecules offer efficacy but relatively shorter half-life after intravitreal injections. To address these challenges, numerous technologies and therapies are [...] Read more.
Age-related macular degeneration (AMD) is the leading cause of vision loss in geriatric population. Intravitreal (IVT) injections are popular clinical option. Biologics and small molecules offer efficacy but relatively shorter half-life after intravitreal injections. To address these challenges, numerous technologies and therapies are under development. Most of these strategies aim to reduce the frequency of injections, thereby increasing patient compliance and reducing patient-associated burden. Unlike IVT frequent injections, molecular therapies such as cell therapy and gene therapy offer restoration ability hence gained a lot of traction. The recent approval of ocular gene therapy for inherited disease offers new hope in this direction. However, until such breakthrough therapies are available to the majority of patients, antibody therapeutics will be on the shelf, continuing to provide therapeutic benefits. The present review aims to highlight the status of pre-clinical and clinical studies of neovascular AMD treatment modalities including Anti-VEGF therapy, upcoming bispecific antibodies, small molecules, port delivery systems, photodynamic therapy, radiation therapy, gene therapy, cell therapy, and combination therapies. Full article
(This article belongs to the Special Issue The Molecular Pharmaceutics and Drug Delivery)
Show Figures

Graphical abstract

Back to TopTop